[Prescription and surveillance of treatment by a systemic agent or biotherapy in psoriasis].
Service de Dermatologie, Hôpital La Grave, Place Lange, TSA 60033, 31059 Toulouse cedex, France. boulinguez.s@chu-toulouse.fr
S
S
Boulinguez
D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D016572:Cyclosporine / Q000627:therapeutic use*; D004333:Drug Administration Routes; D016903:Drug Monitoring; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases; D055985:Latent Tuberculosis / Q000150:complications; D008103:Liver Cirrhosis / Q000139:chemically induced; D008487:Medical History Taking; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control; D011565:Psoriasis / Q000188:drug therapy*; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014611:Vaccination
D001688:Biological Products; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D005492:Folic Acid; D008727:Methotrexate